The right option depends on your health history, goals, and what a licensed provider determines is appropriate for your individual situation
Unadjusted populations for semaglutide and tirzepatide differ Using Truveta Data, Truveta Research began with a patient population of over 40,000 patients with overweight or obesity initiating either semaglutide or tirzepatide between May 2022 and September 2023
Despite the low incidence of rhabdomyolysis from statins, muscle-related side effects remain a common reason for stopping this therapy
Of course, these are serious health complications requiring urgent medical attention
Many individuals benefit from continuous or maintenance-phase dosing to preserve weight loss and prevent the biological drive toward regain that occurs after discontinuation
This is your chance to work on your relationship with food in a way that sets you up for long-term success